| Literature DB >> 35921146 |
Samantha M R Kling1, Erika A Saliba-Gustafsson1, Marcy Winget1, Maria A Aleshin2, Donn W Garvert1, Alexis Amano1, Cati G Brown-Johnson1, Bernice Y Kwong2, Ana Calugar2, Ghida El-Banna2, Jonathan G Shaw1, Steven M Asch1,3, Justin M Ko2.
Abstract
BACKGROUND: Both clinicians and patients have increasingly turned to telemedicine to improve care access, even in physical examination-dependent specialties such as dermatology. However, little is known about whether teledermatology supports effective and timely transitions from inpatient to outpatient care, which is a common care coordination gap.Entities:
Keywords: care coordination; care transitions; dermatology; discharge planning; follow-up; inpatient; mixed methods; mobile phone; outpatient; smartphone; teledermatology; telehealth; telemedicine; video visits
Mesh:
Year: 2022 PMID: 35921146 PMCID: PMC9386584 DOI: 10.2196/38792
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 7.076
Outcomes, definitions, and data sources used to evaluate the use, impact, and sustainability of teledermatology for patients transitioning from inpatient to outpatient dermatology follow-up care.
| Outcomes and definitions | Data sources | ||||
|
| |||||
|
|
| ||||
|
|
| Scheduled follow-up within 90 days after discharge | Patient-level scheduling data | ||
|
|
| Completed follow-up within 90 days after discharge | Patient-level scheduling data | ||
|
| |||||
|
| Number and proportion of follow-up visits completed over video within 90 days after discharge | Patient-level scheduling data | |||
|
| Acceptability of teledermatology for postdischarge follow-up patients among clinicians, residents, schedulers, and patients | Clinician and scheduler interviews | |||
|
| |||||
|
| Perceived fit or compatibility of teledermatology within this setting, particularly for patients transitioning from inpatient to outpatient dermatology care | Clinician and scheduler interviews | |||
|
| |||||
|
|
| ||||
|
|
| Days from hospital discharge to initial scheduling for in-clinic and video visits | Patient-level scheduling data | ||
|
|
| Days from hospital discharge to finalized scheduling for in-clinic and video visits | Patient-level scheduling data | ||
|
|
| Perceived impact of teledermatology on scheduling efficiency | Clinician and scheduler interviews | ||
|
|
| ||||
|
|
| Days from hospital discharge to follow-up visit completion for in-clinic and video visits | Patient-level scheduling data | ||
|
|
| Number and proportion of patients who attended follow-up within 14 days after discharge (local benchmark) | Patient-level scheduling data | ||
|
|
| ||||
|
|
| Number and proportion of patients who scheduled but did not complete a teledermatology or in-clinic visit | Patient-level scheduling data | ||
|
|
| Perceived impact of teledermatology on follow-up visit completion | Clinician and scheduler interviews | ||
|
| |||||
|
| Perceived long-term sustainability of video visits and the barriers need to be addressed to improve clinician, scheduler, and patient experience | Clinician and scheduler interviews | |||
Characteristics of patients who potentially needed outpatient postdischarge follow-up dermatology care following an inpatient dermatology consultation during one of three periods: baseline (N=194), early teledermatology (N=218), and sustained teledermatology (N=256).
| Patient characteristics | Baseline (before teledermatology; June to September 2019), n (%) | Early teledermatology (June to September 2020), n (%) | Sustained teledermatology (February to May 2021), n (%) | |
| Patients with inpatient dermatology consultation | 194 (100) | 218 (100) | 256 (100) | |
|
| ||||
|
| Female | 100 (51.5) | 116 (53.2) | 135 (52.7) |
|
| Male | 94 (48.5) | 102 (46.8) | 121 (47.3) |
|
| ||||
|
| 0-29 | 19 (9.8) | 27 (12.4) | 34 (13.3) |
|
| 30-49 | 37 (19.1) | 48 (22) | 69 (27) |
|
| 50-69 | 83 (42.8) | 82 (37.6) | 92 (35.9) |
|
| ≥70 | 55 (28.4) | 61 (28) | 61 (23.8) |
|
| ||||
|
| 0-20 | 90 (46.4) | 104 (47.7) | 133 (52) |
|
| ≥21 | 104 (53.6) | 114 (52.3) | 123 (48) |
|
| ||||
|
| Private | 42 (21.6) | 28 (12.8) | 40 (15.6) |
|
| Public | 148 (76.3) | 187 (85.8) | 210 (82) |
|
| Other or no insurance identified | 4 (2.1) | 3 (1.4) | 6 (2.3) |
|
| ||||
|
| Emergency department | 25 (12.9) | 40 (18.3) | 56 (21.9) |
|
| Inpatient | 169 (87.1) | 178 (81.7) | 200 (78.1) |
|
| ||||
|
| Dermatology | 63 (32.5) | 91 (41.7) | 97 (37.9) |
|
| Dermato-oncology | 39 (20.1) | 41 (18.8) | 31 (12.1) |
|
| No follow-up | 92 (47.4) | 86 (39.4) | 128 (50) |
aMedian distance between the patient’s zip code and the primary dermatology clinic in Palo Alto, CA, United States, was 21 miles.
Figure 1Number and percentage of patients discharged following an inpatient dermatology consultation and who were scheduled for and completed an outpatient dermatology follow-up visit within 90 days after discharge in the clinic or via video. *P=.99 indicating no difference between baseline, early teledermatology, and sustained teledermatology phases. **P=.04 indicating significant difference between the early and sustained teledermatology phases. ***A local benchmark. ****P=.15 indicating no difference between the teledermatology and in-clinic follow-ups during the early teledermatology phase. *****P=.29 indicating no difference between the teledermatology and in-clinic follow-ups during the sustained teledermatology phase.
Completion of in-clinic and video outpatient dermatology postdischarge follow-up visits (by patient age and location) for patients who received an inpatient dermatology consultation and were discharged across 3 periods: baseline, early teledermatology, and sustained teledermatology.
| Follow-up visit modality | Baseline (before teledermatology; June to September 2019) | Early teledermatology (June to September 2020) | Sustained teledermatology (February to May 2021) | ||||||||
|
| Total visits, N | In-clinic, n (%) | Total visits, N | In-clinic, n (%) | Video, n (%) | Total visits, N | In-clinic, n (%) | Video, n (%) | |||
|
| .32 |
| .47 | ||||||||
|
| <70 | 56 | 56 (100) | 72 | 30 (42) | 42 (58) |
| 71 | 36 (51) | 35 (49) |
|
|
| ≥70 | 18 | 18 (100) | 29 | 9 (31) | 20 (69) |
| 29 | 17 (59) | 12 (41) |
|
|
| .15 |
| .01 | ||||||||
|
| <21 | 36 | 36 (100) | 47 | 19 (40) | 28 (60) |
| 59 | 38 (64) | 21 (36) |
|
|
| ≥21 | 38 | 38 (100) | 54 | 20 (37) | 34 (63) |
| 41 | 15 (37) | 26 (63) |
|
aDifferences in proportion between in-clinic and video visits were determined using chi-square tests.
bThe median distance between the patient’s zip code and the primary dermatology clinic in Palo Alto, CA, United States was 21 miles.
Days from inpatient discharge to initial scheduling, final scheduling, and completion of outpatient dermatological follow-up visits for patients who received an inpatient dermatology consultation and were discharged during 3 periods: baseline, early teledermatology, and sustained teledermatology.
| Follow-up visit modality | Baseline (before teledermatology; June to September 2019) | Early teledermatology (June to September 2020) | Sustained teledermatology (February to May 2021) | |||||||
|
| In-clinic | In-clinic | Video | In-clinic | Video | |||||
| Patients who completed follow-up ≤90 days after discharge, N | 74 | 39 | N/Ab | 62 | N/A | 53 | N/A | 47 | N/A | |
|
| ||||||||||
|
| Initial scheduling of outpatient follow-up | 4.2 (7.2) | 8.5 (10.2) | .01 | 4.3 (6.8) | .89 | 3.0 (4.8) | .40 | 3.7 (10.1) | .76 |
|
| Final scheduling of outpatient follow-up | 9.0 (13.5) | 14.9 (17.8) | .02 | 6.4 (7.6) | .22 | 7.6 (11.2) | .51 | 5.7 (12.3) | .18 |
|
| Completed outpatient follow-up | 19.0 (14.8) | 25.5 (21.9) | .19 | 17.3 (15.1) | .94 | 19.0 (17.7) | .99 | 18.4 (19.4) | .94 |
aDifference from baseline was determined using least squares means in generalized linear regression and was adjusted for multiple comparisons.
bN/A: not applicable.